Each month at The Native Antigen Company we bring you the most relevant infectious disease news from across the globe.
View in browser
TNAC_2025-6_Newsletter Header

Please find the next edition of the Monthly Infectious Diseases Summary, our subjective look at the most important news of the month. Please let us know how you like it and if there is something interesting, we missed by contacting us at nac.contact@lgcgroup.com

TNAC-Newsletter-Image-mosquito

West Nile Virus Detected in UK Mosquitoes for First Time 

West Nile virus has been detected in UK mosquitoes for the first time, in samples collected near Retford, Nottinghamshire. Although the UK Health Security Agency (UKHSA) says the risk to the public is very low, the virus's appearance is likely linked to climate change and expanding mosquito habitats. Most infected individuals have mild or no symptoms, though severe cases can cause neurological disease. Authorities recommend reducing standing water and using repellents. Read more >> 

 

The Native Antigen Company offers a comprehensive range of West Nile virus proteins, ideal for use in your next seroprevalence or diagnostic study.  

TNAC-Newsletter-Image_Reunion-Island

Chikungunya Outbreak in France  

In August 2024, Réunion (France) reported its first local case of chikungunya in a decade, with symptom onset on 12 August. Although surveillance indicators like emergency and primary care visits have declined since week 17, the outbreak has grown significantly. As of 4 June 2025, nearly 53,000 confirmed local cases have been recorded. The virus has led to 20 deaths, mainly in elderly individuals with underlying health issues and two infants under six months Read more >>. 

 

At The Native Antigen Company, we offer an extensive range of Chikungunya antigens and antibodies  including our unique mammalian expressed recombinant virus-like particles to support IVD assay development and vaccine R&D. 

TNAC-Newsletter-Image-Norovirus

GII.17 Norovirus Emerges as Dominant US Strain in Outbreaks 

A recent study published on June 02, 2025, in the journal of Emerging Infectious Diseases highlights a major shift in norovirus outbreaks in the US, with genotype GII.17 overtaking the long-dominant GII.4 strain between 2022 and 2025. By the 2024–25 season, GII.17 accounted for 75% of all outbreaks. This emergence also coincided with changes in seasonal patterns, including an unusually early start to the 2024–25 season in October and prolonged activity during the previous year.  Read more >> 

 

The Native Antigen Company offers a comprehensive list of Norovirus antigens and antibodiesand and high purity virus-like particles (VLPs), ideal for developing sensitive diagnostics and supporting ongoing surveillance efforts. 

Join The Conversation

TWiV Podcast Icon

Alternative vax and pandemic origins

LISTEN NOW
Microbe Mail Icon

Malaria vaccines: The English episode

LISTEN NOW
ECDC On Air Icon_SDG

Europe's SDG Reality Check

LISTEN NOW

The Latest from The Native Antigen Company

New Blog Post

Recombinant Rheumatoid Factor: Elevating Autoimmune Diagnostics

 

Have you been struggling to find the critical human health proteins needed for rheumatoid clinical testing? Have you ever considered using recombinant proteins?

Our latest blog delves into the significant role of recombinant proteins, particularly Rheumatoid Factor, for diagnostic uses like rheumatoid arthritis testing. Recombinant proteins serve as an alternative to native proteins in assays. They are crucial in the diagnostic landscape, offering consistency, scalability, and being pathogen-free.

We're also thrilled to announce the upcoming launch of our Recombinant Rheumatoid Factor! This innovative product is designed to assist laboratory professionals in accurately testing for autoimmune diseases such as Rheumatoid Arthritis. Find details about this and more by clicking below.

READ NOW

Chikungunya Case Study

Unlocking High Resolution Structural Insights from Virus-Like Particles

 

Virus-Like Particles (VLPs) have emerged as indispensable tools. They can be utilized for applications in vaccine research, diagnostics, and therapeutic development.

The partnership between The Native Antigen Company and PUXANO has resulted in an innovative case study on the structural elucidation of Chikungunya Virus-Like Particles.

Our latest white paper delves into this collaborative effort, showcasing the unparalleled potential of combining expertise to advance research programs with valuable structural insights.

Don't miss out on the opportunity to learn more about how this unique synergy can drive your research forward.

DOWNLOAD

CDx Email Footer - All Companies

The Native Antigen Company, LGC Unit 3, Oxford Technology Park, Kidlington, Oxford, Oxfordshire OX5 1GN, United Kingdom, +441865595230

Unsubscribe Manage preferences